General description
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.
INN
Bevacizumab
Medicine type
Biological agent
EML status history
First added in 2013
(TRS
985)
for
Age related macular degeneration
Application rejected in 2025
(TRS
1064)
for
Hepatocellular carcinoma of liver
Wikipedia
DrugBank
Recommendations
Section
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications
Section
Immunomodulators
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
Indications